GSA CAPITAL PARTNERS LLP - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.

Quarter-by-quarter ownership
GSA CAPITAL PARTNERS LLP ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2021$568,000
+148.0%
172,056
+185.6%
0.06%
+123.1%
Q2 2021$229,000
+136.1%
60,238
+137.7%
0.03%
+62.5%
Q1 2021$97,000
+67.2%
25,344
+102.8%
0.02%
+6.7%
Q1 2020$58,00012,5000.02%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders